Cloak your photos with this AI privacy tool to fool facial recognition – The Verge

Ubiquitous facial recognition is a serious threat to privacy. The idea that the photos we share are being collected by companies to train algorithms that are sold commercially is worrying. Anyone can buy these tools, snap a photo of a stranger, and find out who they are in seconds. But researchers have come up with a clever way to help combat this problem.

The solution is a tool named Fawkes, and was created by scientists at the University of Chicagos Sand Lab. Named after the Guy Fawkes masks donned by revolutionaries in the V for Vendetta comic book and film, Fawkes uses artificial intelligence to subtly and almost imperceptibly alter your photos in order to trick facial recognition systems.

The way the software works is a little complex. Running your photos through Fawkes doesnt make you invisible to facial recognition exactly. Instead, the software makes subtle changes to your photos so that any algorithm scanning those images in future sees you as a different person altogether. Essentially, running Fawkes on your photos is like adding an invisible mask to your selfies.

Scientists call this process cloaking and its intended to corrupt the resource facial recognition systems need to function: databases of faces scraped from social media. Facial recognition firm Clearview AI, for example, claims to have collected some three billion images of faces from sites like Facebook, YouTube, and Venmo, which it uses to identify strangers. But if the photos you share online have been run through Fawkes, say the researchers, then the face the algorithms know wont actually be your own.

According to the team from the University of Chicago, Fawkes is 100 percent successful against state-of-the-art facial recognition services from Microsoft (Azure Face), Amazon (Rekognition), and Face++ by Chinese tech giant Megvii.

What we are doing is using the cloaked photo in essence like a Trojan Horse, to corrupt unauthorized models to learn the wrong thing about what makes you look like you and not someone else, Ben Zhao, a professor of computer science at the University of Chicago who helped create the Fawkes software, told The Verge. Once the corruption happens, you are continuously protected no matter where you go or are seen.

The group behind the work Shawn Shan, Emily Wenger, Jiayun Zhang, Huiying Li, Haitao Zheng, and Ben Y. Zhao published a paper on the algorithm earlier this year. But late last month they also released Fawkes as free software for Windows and Macs that anyone can download and use. To date they say its been downloaded more than 100,000 times.

In our own tests we found that Fawkes is sparse in its design but easy enough to apply. It takes a couple of minutes to process each image, and the changes it makes are mostly imperceptible. Earlier this week, The New York Times published a story on Fawkes in which it noted that the cloaking effect was quite obvious, often making gendered changes to images like giving women mustaches. But the Fawkes team says the updated algorithm is much more subtle, and The Verges own tests agree with this.

But is Fawkes a silver bullet for privacy? Its doubtful. For a start, theres the problem of adoption. If you read this article and decide to use Fawkes to cloak any photos you upload to social media in future, youll certainly be in the minority. Facial recognition is worrying because its a society-wide trend and so the solution needs to be society-wide, too. If only the tech-savvy shield their selfies, it just creates inequality and discrimination.

Secondly, many firms that sell facial recognition algorithms created their databases of faces a long time ago, and you cant retroactively take that information back. The CEO of Clearview, Hoan Ton-That, told the Times as much. There are billions of unmodified photos on the internet, all on different domain names, said Ton-That. In practice, its almost certainly too late to perfect a technology like Fawkes and deploy it at scale.

Naturally, though, the team behind Fawkes disagree with this assessment. They note that although companies like Clearview claim to have billions of photos, that doesnt mean much when you consider theyre supposed to identify hundreds of millions of users. Chances are, for many people, Clearview only has a very small number of publicly accessible photos, says Zhao. And if people release more cloaked photos in the future, he says, sooner or later the amount of cloaked images will outnumber the uncloaked ones.

On the adoption front, however, the Fawkes team admits that for their software to make a real difference it has to be released more widely. They have no plans to make a web or mobile app due to security concerns, but are hopeful that companies like Facebook might integrate similar tech into their own platform in future.

Integrating this tech would be in these companies interest, says Zhao. After all, firms like Facebook dont want people to stop sharing photos, and these companies would still be able to collect the data they need from images (for features like photo tagging) before cloaking them on the public web. And while integrating this tech now might only have a small effect for current users, it could help convince future, privacy-conscious generations to sign up to these platforms.

Adoption by larger platforms, e.g. Facebook or others, could in time have a crippling effect on Clearview by basically making [their technology] so ineffective that it will no longer be useful or financially viable as a service, says Zhao. Clearview.ai going out of business because its no longer relevant or accurate is something that we would be satisfied [with] as an outcome of our work.

See original here:

Cloak your photos with this AI privacy tool to fool facial recognition - The Verge

Viewpoint: Using AI to Identify Work Comp Fraud Related to COVID-19 – Claims Journal

As employees return to work after the COVID-19 crisis has subsided, insurers and employers will likely experience a surge in claims related to the virus. Analysts expect coverages for workers compensation, employer liability, and business interruption to be especially hard hit.[i] The California Workers Compensation Insurance Rating Bureau estimates annual losses in its state will be $1.2 billion.[ii] Extrapolating nationally, losses would be approximately $5 billion.

Most states have enacted legislation or executive orders to designate critical occupations in the wake of the virus. For workers compensation, certain front-line occupations (such as health care and first responders) will be presumptively covered in most states. According to data scientists at CLARA analytics, health care workers experienced a fourfold increase in virus-related claims since February 2020. This presumption may extend beyond the front line to include all employees in all occupations working outside the home regardless of direct risk.[iii]

The new COVID-19 laws and executive orders are sometimes ambiguous and could lead to disputes. Many questions will arise: Where and when did exposure to the virus occur? Did multiple employees at the same location suffer from the virus? Job classifications will be important: Do medical intake workers have the same level of exposure as nurses employed at the same hospital?

Also, medical treatment may raise additional questions: Was the COVID-19 test administered in a timely fashion? Are these tests carried out at a nationally recognized testing lab (NRTL)? Do the tests generate a high rate of false negatives?

In addition, given the current massive level of unemployment, we may see a surge in post-termination cumulative trauma claims. If a terminated worker tests positive, attorneys may allege he or she was exposed to the virus at his or her prior workplace (even if a test was not conducted during the period of employment). Moreover, if the worker suffers from any other medical condition, a COVID-19 diagnosis may be added as an aggravating factor.

Beyond workers compensation, health insurers forecast increases in fraud.[iv] Medicare has already experienced a rise in provider fraud due to COVID-19.[v]

Workers compensation claims fraud is supplier driven. A small segment of attorneys and medical providers exploit the system to file fraudulent claims. The pandemic offers these fraudsters an opportunity to revive practices that have been proven successful in the past. For example, the massive layoffs caused by dislocations resulting from COVID -19 may provoke some fraudsters to retain cappers. These intermediaries recruit laid-off employees in order to file workers compensation claims. The employees will be sent to networks which may include chiropractors, pharmacists, diagnostic facilities, medical equipment suppliers, and interpreters. In the wake of COVID- 19, pulmonologists, testing labs, and respiratory therapists may be recruited.

Attorney Data

Attorneys are the claims quarterbacks handing off workers to an entire array of vendors starting with medical providers. Attorneys are paid at settlement and, unlike medical providers, are not recorded in bill review systems. As a result, attorney data has been difficult to isolate. However, new AI tools can reliably identify attorney behavior over the course of many claims.

To detect attorney involvement in fraudulent claims, analysts start with a list of medical providers who have been publicly identified as fraudulent. They then work backward via longitudinal analysis to identify attorneys who originally refer to these providers. Attorney data is gleaned from claims notes and utilization review appeals. Accounts payable systems reveal final settlement information. This information can be used to identify attorneys and their firms.

Medical Provider Data

Using a multiyear, multipayer database, data scientists can identify a reliable picture of medical provider practice patterns. By tapping into bill review information, analysts can detect billing patterns, diagnoses, procedure codes, drug prescribing, and referrals. Excessive or inaccurate billing are common indicators of fraud. Given that many bills are disallowed, these providers usually display large gaps between billed and paid amounts.

Fraud Network Data

These complex networks consisting of multiple coordinated vendors are key drivers of fraud. AI can detect usually hidden connections between attorneys, medical providers, and other vendors, enabling data scientists to track their progression over time. These analysts can employ clustering techniques to graphically show cross-referrals. The analysis starts with the first provider as the node and includes other central and peripheral providers.

Putting Data into Action

To combat fraudulent COVID-19 claims, payers can now employ artificial intelligence tools to mine a multiyear, cross-payer claims database. Data scientists can track both attorneys and medical providers and the progression of fraud networks. CLARA analytics has created claims alerts to notify examiners when a claim deviates from expected patterns. Fraudsters are sometimes a major source of such deviations. Using these alerts, payers can intervene early to curb cost escalation or to shut down the claim entirely.

Tapping into aggregate attorney, medical provider, and network data will improve the efficiency and focus of specialized investigative units. At present, most of these units rely on one-off referrals from their own companies. By using a multipayer, multiyear database, payers can harvest a list of suspicious attorneys and providers. Claims examiners can intervene early to forestall a costly chain of referrals. Depending on the rules of each state, payers may be able to redirect the claims to their own preferred provider networks.

In sum, COVID-19 will account for a surge in workers compensation claims. The billions of dollars in additional costs may exceed those of the recession of 2008. In order to effectively handle the valid claims, payers must quickly and accurately eliminate the few fraudulent ones. Artificial intelligence tools can be deployed to identify fraud. Payers can then focus attention on helping patients who are the real victims of COVID-19.

[i] Gabriel Olano, Figuring out the new world post-coronavirus, Corporate Risk and Insurance, May 21, 2020.

[ii] WCIRB Wire, WCIRB Evaluates Governors COVID-19 Executive Order Impact on Workers Compensation Costs, May 22, 2020.

[iii] Alex Swedlow, Rena David and Mark Webb, Integrating COVID-19 Presumptions into the California Workers Compensation System, CWCI, May 2020.

[iv] Michael Adelberg and Melissa Garrido, The COVID-19 Epidemic As A Catalyst For Health Care Fraud, Health Affairs, May 7, 2020.

[v] Federal News Network, Combating health care fraud as CMS loosens rules to respond to coronavirus, May 18, 2020.

About Gregory Johnson Johnson is a health care consultant with 30 years experience in health care and insurance. He was previously a partner at Ernst & Young and PricewaterhouseCoopers, as well as director of medical analytics at the California Workers' Compensation Insurance Rating Bureau. He holds a Bachelor of Arts from University of Oregon and a Ph.D. from Harvard University.

Link:

Viewpoint: Using AI to Identify Work Comp Fraud Related to COVID-19 - Claims Journal

Introducing The AI & Machine Learning Imperative – MIT Sloan

Topics The AI & Machine Learning Imperative

The AI & Machine Learning Imperative offers new insights from leading academics and practitioners in data science and artificial intelligence. The Executive Guide, published as a series over three weeks, explores how managers and companies can overcome challenges and identify opportunities by assembling the right talent, stepping up their own leadership, and reshaping organizational strategy.

Leading organizations recognize the potential for artificial intelligence and machine learning to transform work and society. The technologies offer companies strategic new opportunities and integrate into a range of business processes customer service, operations, prediction, and decision-making in scalable, adaptable ways.

As with other major waves of technology, AI requires organizations and managers to shed old ways of thinking and grow with new skills and capabilities. The AI & Machine Learning Imperative, an Executive Guide from MIT SMR, offers new insights from leading academics and practitioners in data science and AI. The guide explores how managers and companies can overcome challenges and identify opportunities across three key pillars: talent, leadership, and organizational strategy.

Email Updates on AI, Data & Machine Learning

Get monthly email updates on how artificial intelligence and big data are affecting the development and execution of strategy in organizations.

Please enter a valid email address

Thank you for signing up

Privacy Policy

The series launches Aug. 3, and summaries of the upcoming articles are included below. Sign up to be reminded when new articles launch in the series, and in the meantime, explore our recent library of AI and machine learning articles.

In order to achieve the ultimate strategic goals of AI investment, organizations must broaden their sights beyond creating augmented intelligence tools for limited tasks. To prepare for the next phase of artificial intelligence, leaders must prioritize assembling the right talent pipeline and technology infrastructure.

Recent technical advances in AI and machine learning offer genuine productivity returns to organizations. Nevertheless, finding and enabling talented individuals to succeed in engineering these kinds of systems can be a daunting challenge. Leading a successful AI-enabled workforce requires key hiring, training, and risk management considerations.

AI is no regular technology, so AI strategy needs to be approached differently than regular technology strategy. A purposeful approach is built on three foundations: a robust and reliable technology infrastructure, a specific focus on new business models, and a thoughtful approach to ethics. Available Aug. 10.

CFOs who take ownership of AI technology position themselves to lead an organization of the future. While AI is likely to impact business practices dramatically in the future across the C-suite, its already having an impact today and the time for CFOs to step up to AI leadership is now. Available Aug. 12.

To remain relevant and resilient, companies and leaders must strive to build business models in a way that ensures three key components are working together: AI that enables and powers a centralized data lake of enterprise data, a marketplace of sellers and partners that make individualized offers based on the intelligence of the data collected and powered by AI, and a SaaS platform that is essential for users. Available Aug. 17.

Acquiring the right AI technology and producing results, while critical, arent enough. To gain value from AI, organizations need to focus on managing the gaps in skills and processes that impact people and teams within the organization. Available Aug. 19.

The AI & Machine Learning Imperative offers new insights from leading academics and practitioners in data science and artificial intelligence. The Executive Guide, published as a series over three weeks, explores how managers and companies can overcome challenges and identify opportunities by assembling the right talent, stepping up their own leadership, and reshaping organizational strategy.

Ally MacDonald (@allymacdonald) is a senior editor at MIT Sloan Management Review.

View original post here:

Introducing The AI & Machine Learning Imperative - MIT Sloan

Announcing Sight Tech Global, an event on the future of AI and accessibility for people who are blind or visually impaired – TechCrunch

Few challenges have excited technologists more than building tools to help people who are blind or visually impaired. It was Silicon Valley legend Ray Kurzweil, for example, who in 1976 launched the first commercially available text-to-speech reading device. He unveiled the $50,000 Kurzweil Reading Machine, a boxy device that covered a tabletop, at a press conference hosted by the National Federation of the Blind.

The early work of Kurzweil and many others has rippled across the commerce and technology world in stunning ways. Todays equivalent of Kurzweils machine is Microsofts Seeing AI app, which uses AI-based image recognition to see and read in ways that Kurzweil could only have dreamed of. And its free to anyone with a mobile phone.

Remarkable leaps forward like that are the foundation for Sight Tech Global, a new, virtual event slated for December 2-3, that will bring together many of the worlds top technology and accessibility experts to discuss how rapid advances in AI and related technologies will shape assistive technology and accessibility in the years ahead.

The technologies behind Microsofts Seeing AI are on the same evolutionary tree as the ones that enable cars to be autonomous and robots to interact safely with humans. Much of our most advanced technology today stems from that early, challenging mission that top Silicon Valley engineers embraced to teach machines to see on behalf of humans.

From the standpoint of people who experience vision loss, the technology available today is astonishing, far beyond what anyone anticipated even 10 years ago. Purpose-built products like Seeing AI and computer screen readers like JAWS are remarkable tools. At the same time, consumer products, including mobile phones, mapping apps and smart voice assistants, are game changers for everyone, those with sight loss not the least. And yet, that tech bonanza has not come close to breaking down the barriers in the lives of people who still mostly navigate with canes or dogs or sighted assistance, depend on haphazard compliance with accessibility standards to use websites and can feel as isolated as ever in a room full of people.

In other words, we live in a world where a computer can drive a car at 70 MPH without human assistance but there is not yet any comparable device to help a blind person walk down a sidewalk at 3 MPH. A social media site can identify billions of people in an instant but a blind person cant readily identify the person standing in front of them. Todays powerful technologies, many of them grounded in AI, have yet to be milled into next-generation tools that are truly useful, happily embraced and widely affordable. The work is underway at big tech companies like Apple and Microsoft, at startups, and in university labs, but no one would dispute that the work is as slow as it is difficult. People who are blind or visually impaired live in a world where, as the science fiction author William Gibson once remarked, The future is already here its just not very evenly distributed.

That state of affairs is the inspiration for Sight Tech Global. The event will convene the top technologists, human-computer interaction specialists, product designers, researchers, entrepreneurs and advocates to discuss the future of assistive technology as well as accessibility in general. Many of those experts and technologists are blind or visually impaired, and the event programming will stand firmly on the ground that no discussion or new product development is meaningful without the direct involvement of that community. Silicon Valley has great technologies, but does not, on its own, have the answers.

The two days of programming on the virtual main stage will be free and available on a global basis both live and on-demand. There will also be a $25 Pro Pass for those who want to participate in specialized breakout sessions, Q&A with speakers and virtual networking. Registration for the show opens soon; in the meantime, anyone interested may request email updates here.

Its important to note that there are many excellent events every year that focus on accessibility, and we respect their many abiding contributions and steady commitment. Sight Tech Global aims to complement the existing event line-up by focusing on hard questions about advanced technologies and the products and experiences they will drive in the years ahead assuming they are developed hand-in-hand with their intended audience and with affordability, training and other social factors in mind.

In many respects, Sight Tech Global is taking a page from TechCrunchs approach to its AI and robotics events over the past four years, which were in partnership with MIT and UC Berkeley. The concept was to have TechCrunch editors ask top experts in AI and related fields tough questions across the full spectrum of issues around these powerful technologies, from the promise of automation and machine autonomy to the downsides of job elimination and bias in AI-based systems. TechCrunchs editors will be a part of this show, along with other expert moderators.

As the founder of Sight Tech Global, I am drawing on my extensive event experience at TechCrunch over eight years to produce this event. Both TechCrunch and its parent company, Verizon Media, are lending a hand in important ways. My own connection to the community is through my wife, Joan Desmond, who is legally blind.

The proceeds from sponsorships and ticket sales will go to the nonprofit Vista Center for the Blind and Visually Impaired, which has been serving Silicon Valley area for 75 years. The Vista Center owns the Sight Tech Global event and its executive director, Karae Lisle is the events chair. We have assembled a highly experienced team of volunteers to program and produce a rich, world-class virtual event on December 2-3.

Sponsors are welcome, and we have opportunities available ranging from branding support to content integration. Please email sponsor@sighttechglobal.com for more information.

Our programming work is under way and we will announce speakers and sessions over the coming weeks. The programming committee includes Jim Fruchterman (Benetech / TechMatters), Larry Goldberg (Verizon Media), Matt King (Facebook) and Professor Roberto Manduchi (UC Santa Cruz). We welcome ideas and can be reached via info@sighttechglobal.com

For general inquiries, including collaborations on promoting the event, please contact info@sighttechglobal.com.

Go here to read the rest:

Announcing Sight Tech Global, an event on the future of AI and accessibility for people who are blind or visually impaired - TechCrunch

NIH launches imaging AI collaboration for COVID-19 and beyond – FierceBiotech

The National Institutes of Health is turning to artificial intelligence and imaging scans to not only help detect cases of COVID-19 earlier, but to potentially personalize treatments for the spreading disease.

In lung CT scans, the novel coronavirus leaves telltale signs that distinguish it from other respiratory diseasessmall white spots and a slightly obscuring haze, described by radiologists as ground glass, that indicates fluid build-up and damage to the tissue. Abnormalities are found in the heart scans and ultrasounds of many COVID-19 patients as well.

A collaboration funded by the NIHs National Institute of Biomedical Imaging and Bioengineering aims to develop new diagnostics and machine learning algorithms to quickly assess the severity of an infectionand predict a persons responses to different treatments.

This program is particularly exciting because it will give us new ways to rapidly turn scientific findings into practical imaging tools that benefit COVID-19 patients, NIBIB Director Bruce Tromberg said. It unites leaders in medical imaging and artificial intelligence from academia, professional societies, industry and government to take on this important challenge.

RELATED: Coronavirus tests the value of artificial intelligence in medicine

The resulting Medical Imaging and Data Resource Center will operate a large, open-source repository that will gather COVID-19 chest images from tens of thousands of patients, allowing researchers to evaluate both lung and cardiac tissue data, ask critical research questionsand develop predictive COVID-19 imaging signatures that can be delivered to healthcare providers, said Guoying Liu, director of the NIBIBs MRI program.

The database will be hosted at the University of Chicago, and co-led by a trio of medical imaging societies: the American College of Radiology, the Radiological Society of North America and the American Association of Physicists in Medicine.

In addition, the center will support five infrastructure development projects and oversee 12 research projects, covering about 20 university labsall with an initial focus on COVID-19, but with plans to expand its imaging data services and AI development to other diseases in the future.

RELATED: To screen COVID-19 patients for heart problems, FDA clears several ultrasound, AI devices

COVID-19 is our immediate target, but the MIDRC will ultimately enable the medical and scientific communities to mobilize images and data for work against other existing diseases and future healthcare threats, said the University of Washingtons Paul Kinahan, chair of the AAPMs research committee.

See original here:

NIH launches imaging AI collaboration for COVID-19 and beyond - FierceBiotech

9 Saint Lucia Resorts That Are Open Right Now Caribbean Journal – Caribbean Journal

Saint Lucia was one of the first destinations to relaunch tourism when the island reopened its borders at the beginning of June, and its open to tourists including those from the United States.

What youll find in Saint Lucia are many resorts with widely spaced accommodations ideal for social distancing, and strong safety protocols for hotels, transportation, and attractions.

All travelers to Saint Lucia must submit a pre-arrival travel registration form and proof of having received a negative COVID-19 PCR test within seven days of arrival on-island. Visitors must have reservations at (and confie to) a hotel that has been certified as compliant with Saint Lucias COVID-19 safety protocols in order to be admitted into the country. (See more on the islands policies here). Happily, Saint Lucias diverse hotel stock specializes in resorts youll never want to leave.

So where can you stay if youre planning to visit? Here are the resorts that have received COVID-19 certification and are open right now.

Ladera: Three-walled suites 1,000 feet above the beach and with spectacular views of the Piton mountains make a stay at Ladera seem otherworldly in other words, the perfect place for escape. Just 37 rooms means plenty of elbow room for guests.

Read the original post:

9 Saint Lucia Resorts That Are Open Right Now Caribbean Journal - Caribbean Journal

Royal Caribbean, Marriott and Cisco Earnings on Tap in Week Ahead – TheStreet

Next week will see earnings reports from a hard-hit cruise operator, a hotel operator and a networking giant, among others.

Royal Caribbean Cruises Ltd. (RCL) - Get Report is expected to report a loss of $988.5 million, or $4.82 a share, on sales of $47.4 million before the market opens on Monday, based on a FactSet survey of 12 analysts.

In the same period a year ago, the company posted earnings of $2.54 a share on sales of $2.8 billion. It reported net income of $249.7 million.

The stock has risen 25.5% since the company last reported earnings on May 20.

In the upcoming quarter, analysts are forecasting a loss of $931.2 million, or $4.65 a share, on sales of $212.5 million.

For the year, analysts project revenue of $3 billion.

Marriott International, Inc. (MAR) - Get Report is expected to report a loss of $136.3 million, or 41 cents a share, on sales of $1.7 billion after the market closes on Monday, based on a FactSet survey of 23 analysts.

In the same period a year ago, the company posted earnings of $1.56 a share on sales of $5.3 billion. It reported net income of $375 million.

The stock has risen 9.8% since the company last reported earnings on May 11.

In the upcoming quarter, analysts are forecasting adjusted net income of $35.5 million, or 15 cents a share, on sales of $2.6 billion.

For the year, analysts project revenue of $12.2 billion.

Occidental Petroleum Corporation (OXY) - Get Report is expected to report a loss of $1.52 billion, or $1.68 a share, on sales of $3.9 billion after the market closes on Monday, based on a FactSet survey of 23 analysts.

In the same period a year ago, the company posted earnings of 97 cents a share on sales of $4.4 billion. It reported net income of $628 million.

The stock has risen 0.9% since the company last reported earnings on May 5.

In the upcoming quarter, analysts are forecasting a loss of $726.3 million, or 75 cents a share, on sales of $4.6 billion.

For the year, analysts project revenue of $19.2 billion.

Cisco Systems, Inc. (CSCO) - Get Report is expected to report net income of $3.1 billion, or 74 cents a share, on sales of $12.1 billion after the market closes on Wednesday, based on a FactSet survey of 25 analysts.

In the same period a year ago, the company posted earnings of 83 cents a share on sales of $13.4 billion. It reported net income of $3 billion.

The company offered guidance of 72 to 74 cents a share on May 14, a day after its last financial report. Shares have risen 8.9% since then.

In the upcoming quarter, analysts are forecasting net income of $3.2 billion, or 75 cents a share, on sales of $12.2 billion.

For the year, analysts project revenue of $49.2 billion.

Applied Materials, Inc. (AMAT) - Get Reportis expected to report net income of $881.3 million, or 95 cents a share, on sales of $4.2 billion after the market closes on Thursday, based on a FactSet survey of 23 analysts.

In the same period a year ago, the company posted earnings of 74 cents a share on sales of $3.6 billion. It reported net income of $666 million.

The stock has risen 16.9% since the company last reported earnings on May 14.

In the upcoming quarter, analysts are forecasting net income of $942.7 million, or $1.02 a share, on sales of $4.4 billion.

For the year, analysts project revenue of $16.6 billion.

Applied Materials is currently trading at a price-to-forward-earnings ratio of 15.3 based on the 12-month estimates of 25 analysts surveyed by FactSet.

Read what Jim Cramer is telling his investment club members about earnings season at Action Alerts PLUS.

Originally posted here:

Royal Caribbean, Marriott and Cisco Earnings on Tap in Week Ahead - TheStreet

Belgium and the Bahamas off safe list – ABTA Magazine

Change comes into place on 4am on Saturday August

Travellers arriving in the UK fromBelgium, Andorra and the Bahamas will be forced to quarantine for 14 days after the countries were removed from the governments travel corridors list.

The Department for Transport said that data from the joint biodiversity centre and Public Health England indicated a significant change in both the level and pace of confirmed cases in the countries.

The change comes into place on 4am on Saturday August 8. Scotland has also withdrawn the countries from its list.

The Foreign & Commonwealth Office now advises against all but essential travel to Belgium, Andorra and the Bahamas.

Data shows we need to remove Andorra, Belgium and The Bahamas from our list of #coronavirus Travel Corridors in order to keep infection rates DOWN. If you arrive in the UK after 0400 Saturday from these destinations, you will need to self-isolate for 14 days.

Belgium recoded more than 70,000 Covid-19 cases this week, meaning it has a rate of 27.8 new cases per 100,000 people. This is compared to the UKs 8.4.

Estonia, Latvia, Slovakia,Slovenia, and St Vincent and the Grenadines were added to the list on July 24, butSpainwas removed on July 25 andLuxembourgwas removed on July 31.

More: Get information on overseas travel in our travel advice sectionMore: Sign up to our Weekly Digest for an overview of travel news

The government is under increased pressure to implement a testing regime at borders amid the confusion caused by changes to thetravel corridors list.

In the wake of the Department for Transport removingSpainfrom its safe list and the change in FCO advice, which was subsequentlyextended toinclude the Canary and BalearicIslands, the chief executive of Heathrow has renewedcalls for testing.

As many of our customers have experienced, its difficult to plan a holiday that way, let alone run a business.Testing offers a way to safely open up traveland trade to some of the UKs biggest markets which currently remain closed, John Holland-Kaye told BBC Radio 4sTodayprogramme.

He said: The UK needs a passenger testing regime and fast, adding that without it, Britain is just playing a game of quarantine roulette.

Matt Hancock has said he hasabsolutely no regrets about the quickchange in advice on Spain and saidmore countries could be removed from the exemption list within days.

The health secretary said officials were looking all of the time at coronavirus cases in other countries.

See original here:

Belgium and the Bahamas off safe list - ABTA Magazine

Belgium, Andorra and Bahamas have been added to the UK quarantine list – heres why – Leighton Buzzard Observer

Travellers arrivng in the UK from Belgium will now be required to quarantine for 14 days (Getty Images)

Travellers arriving in the UK from Belgium, the Bahamas and Andorra will be required to quarantine for 14 days.

The new measure comes into place from Saturday 8 August, except in Wales where the restriction is already in place.

The trio of countries follow Spain and Luxembourg in having a quarantine reimposed, with the Foreign and Commonwealth Office warning against all but essential travel to the three countries.

When do the measures get underway?

The Transport Secretary revealed the changes on Thursday night.

He tweeted: Data shows we need to remove Andorra, Belgium and the Bahamas from our list of [coronavirus] travel corridors in order to keep infection rates DOWN.

"If you arrive in the UK after 0400 Saturday from these destinations, you will need to self-isolate for 14 days."

Scottish Justice Secretary Humza Yousuf said there was a shared understanding between all home nations that the measures were required.

Wales have already implemented the quarantine restrictions.

The measures apply to anyone travelling through Belgium on their return from other European or World destinations.

Why have the measures been introduced?

Belgium has seen a rise in cases in recent weeks with data showing 27.8 new cases per 100,000 people compared to UKs 8.4.

The weekly case rate has spiked in The Bahamas at 77.8, while Andorra has seen a five-fold increase in cases since mid-July.

According to the Guardian measures could be introduced for France amid a rise in cases.

Are there any new travel corridors?

UK travellers have been told it is now safe to travel to Malaysia and Brunei following a significant dip in cases.

Vaughan Gething, the Welsh health minister said the public health risk posed by a decreasing prevalence was now low enough to open up a travel corridor to the southeast Asian countries.

More:

Belgium, Andorra and Bahamas have been added to the UK quarantine list - heres why - Leighton Buzzard Observer

Tor Browser 9.5.3 Download – TechSpot

Tor is a network of virtual tunnels that allows people and groups to improve their privacy and security on the Internet. It also enables software developers to create new communication tools with built-in privacy features. Tor provides the foundation for a range of applications that allow organizations and individuals to share information over public networks without compromising their privacy.

Note: You can also download the latest beta version, Tor Browser 10 Alpha 1 here.

Individuals use Tor to keep websites from tracking them and their family members, or to connect to news sites, instant messaging services, or the like when these are blocked by their local Internet providers. Tor's hidden services let users publish web sites and other services without needing to reveal the location of the site. Individuals also use Tor for socially sensitive communication: chat rooms and web forums for rape and abuse survivors, or people with illnesses.

Journalists use Tor to communicate more safely with whistleblowers and dissidents. Non-governmental organizations (NGOs) use Tor to allow their workers to connect to their home website while they're in a foreign country, without notifying everybody nearby that they're working with that organization.

Groups such as Indymedia recommend Tor for safeguarding their members' online privacy and security. Activist groups like the Electronic Frontier Foundation (EFF) recommend Tor as a mechanism for maintaining civil liberties online. Corporations use Tor as a safe way to conduct competitive analysis, and to protect sensitive procurement patterns from eavesdroppers. They also use it to replace traditional VPNs, which reveal the exact amount and timing of communication. Which locations have employees working late? Which locations have employees consulting job-hunting websites? Which research divisions are communicating with the company's patent lawyers?

A branch of the U.S. Navy uses Tor for open source intelligence gathering, and one of its teams used Tor while deployed in the Middle East recently. Law enforcement uses Tor for visiting or surveilling web sites without leaving government IP addresses in their web logs, and for security during sting operations.

Welcome Screen

Our old screen had way too much information for the users, leading many of them to spend great time confused about what to do. Some users at the paper experiment spent up to 40min confused about what they needed to be doing here. Besides simplifying the screen and the message, to make it easier for the user to know if they need to configure anything or not, we also did a 'brand refresh' bringing our logo to the launcher.

Censorship circumvention configuration

This is one of the most important steps for a user who is trying to connect to Tor while their network is censoring Tor. We also worked really hard to make sure the UI text would make it easy for the user to understand what a bridge is for and how to configure to use one. Another update was a little tip we added at the drop-down menu (as you can see below) for which bridge to use in countries that have very sophisticated censorship methods.

Proxy help information

The proxy settings at our Tor Launcher configuration wizard is an important feature for users who are under a network that demands such configuration. But it can also lead to a lot of confusion if the user has no idea what a proxy is. Since it is a very important feature for users, we decided to keep it in the main configuration screen and introduced a help prompt with an explanation of when someone would need such configuration.

As part of our work with the UX team, we will also be coordinating user testing of this new UI to continue iterating and make sure we are always improving our users' experience. We are also planning a series of improvements not only for the Tor Launcher flow but for the whole browser experience (once you are connected to Tor) including a new user onboarding flow. And last but not least we are streamlining both our mobile and desktop experience: Tor Browser 7.5 adapted the security slider design we did for mobile bringing the improved user experience to the desktop as well.

Other

What's New:

Tor Browser 9.5.3 is now available from the Tor Browser download page and also from our distribution directory. This release updates Firefox to 68.11.0esr, NoScript to 11.0.34, and Tor to 0.4.3.6.

Also, this release features important security updates to Firefox.

The full changelog since Tor Browser 9.5.1 is:

All Platforms

Note: We are aware of a bug that allows javascript execution on the Safest security level (in some situations). We are working on a fix for this. If you require that javascript is blocked, then you may completely disable it by:

The full changelog since Tor Browser 9.0.5 is:

All Platforms

Build System Windows

View original post here:

Tor Browser 9.5.3 Download - TechSpot

Tor Browser Bundle – Free download and software reviews …

Pros

Good for privacy

Cons

Takes a little bit of understanding

Pros

There were no pros to this program.

Cons

After one search, the results came up empty. After re-installing, the results continued to come up empty.

There is NO UNINSTALL feature. I deleted the program directory and hope that it is actually gone from my computer!

Summary

Do not waste your time downloading this program. You will be disappointed and frustrated.

Pros

None. It's junk.

Cons

Forget this poorly designed piece of garbage. It just plain doesn't work and it's not supported.

The only website that loads is the "Tor Blog". Everything else returns a "bad gateway" message.

Forget about asking for help on the blog. Your "ask a question" message will be rejected because you didn't enter qualifying "tags". There's a link to suggested tags but they're all rejected too. Utterly useless.

I used the "Contact Us" form and they suggested using the "Ask a Question" button on the blog, even after I told them it didn't work because of the asinine "tags" requirement,.

Don't waste your time on this unsupported crap.

Summary

=

Pros

This is really a no brainer is you want to browse anonymously

Cons

can be slow at times but no big deal

Pros

Excelent Project :)Some popular but not easy to find Onion Links:

Hidden Wiki hiwiki544q5q4gbt.onionUncensored Hidden Wiki uhwiki36pbooodfj.onionAlphaBay alphabay54qdm7bn.onionNucleus nucleus4owfwglww.onionSilkRoad V3 reloadxuwmn4gkbe.onion

Cons

i think there is nothing bad about it

Pros

-Reliable-Privacy is great-Secure

Cons

-Slow at times

Pros

Obvious HUGE pros long as one is careful and does there research before using Tor. Im using it solely to get around web filtering at work. GOOD JOB to the folk who decided to not try because they get spooked. Stay smart until your ready for Tor 🙂

Cons

Can cause some problems, just dont be stupid ; )

Summary

Like privacy? Like going around your work places Blocker? This is the thing for you!

Pros

Greate software!

Cons

Greate software!

Pros

It is kind of a cool search tool with apps and much to read and discover. Some of the content is not accessed on the regular web and that is both a blessing for surfers and a curse for TOR's administration, I would think. TOR's administration must have their hands full putting out fires as some of the websites have been raided by the FBI apparently. I'll leave the discussion at that point and leave it to those who wish to research more on the specifics.

Cons

For the average Internet user or just to surf the web, using TOR is fraught with too many warnings about turning off plug ins and many other things people normally do and the reason is security so that you will not break privacy and reveal your IP address, etc. But trying it is a different experience and a lesson in Internet security to some extent.

Summary

The surfing experience lacks the ease and shine of the regular Internet. It is good for users who are concerned about their privacy to quite an extent such as Wikileaks contributors or whistle blowers or if you are in a witness protection program somewhere. Seriously.

Pros

Lets you browse internet without government trying to get up your ass and without companies trying to track everything you do so they can get you to watch their ads to make half a penny off of you. I hate how so many companies wouldnt mind wasting a day of your life to get a few cents from advertising. Its disgusting

Cons

Are none if you download real tor. Its a simple browser and less invasive than any other I know. As in, its not in the battle between firefox, chrome and explorer to become your default browser. Tor is just there when you need it, and stays out of your face completely unless you need it.

https://www.torproject.org/download/download.html.en

Summary

Bing is probably the worst search engine out there. I believe it accepts payments in return for higher placing on the search result so its no wonder that some bullshizz sites come up before the real site when using bing. i tried to download first search result and it was CLEARLY not the real tor but some cookie/virus.

Please Wait

Read the original:

Tor Browser Bundle - Free download and software reviews ...

Experts taught us how to look for online extremism in Monterey County — and what we found is surprising. – Monterey County Weekly

The good news is that online extremism is not thriving in Monterey County as it is elsewhere in the country. The bad news is that corporate gatekeepers keep so much of whats happening on the internet private and proprietary that its impossible to be sure of the above.

TheWeeklyrecently reported on a new research team at the Middlebury Institute of International Studies that uses tech tools to track hate speech, incitement to violence, and how people get radicalized on the internet. As part of the Center on Terrorism, Extremism, and Counterterrorism, they are contributing to a growing field focused on turning the internet into a less dangerous place.

In the spirit of collaboration, CTEC Deputy Director Kris McGuffie and Digital Research Lead Alex Newhouse agreed to train theWeekly, providing a tutorial on how to search for online extremists tied to a certain geographic region, in this case, Monterey County.

The first thing to understand, Newhouse says, is the goals of the extremists on the internet. They want to radicalize as many people as possible, which means they must operate on mainstream social networks like Facebook or YouTube. These platforms have weaknesses that can be exploited, like the tendency of polarizing content to go viral.

After priming audiences with subtle messages of hate, extremists hope to recruit more people into their movement and they do so on niche online communities. They target individual users on video game forums, apps like Discord, or certain groups on Reddit.

Finally, extremists need to develop their groups identity, plan gatherings or demonstrations and eventually violent attacks. That activity happens in designated digital communities, with some known examples being Iron March, Stormfront, KiwiFarms and 8kun.

Each of these online spaces, from Facebook through 8kun, can be classified according to how easily accessible and searchable it is. Theres the regular internet, or Clearnet, which is indexed by search engines and is easy to navigate. The Grey Web refers to invite-only groups or spaces that you have to already know about to reach. The most hidden part of the internet is called the Dark Web. It will never show up on Google results and getting to it requires specialized software such as a Tor browser. The Dark Web is where child pornography is distributed, drug deals are conducted, and where neo-Nazis make plots.

After going over the basics, Newhouse talks about the methods of investigation. This tutorial is taking place on Zoom, so Newhouse begins sharing his screen. The first stop is Facebook where he quickly locates a certain politically focused page with Monterey County in its name. He scrolls down to reach the sidebar suggesting Related Pages. This sidebar is populated by a recommendation algorithm, which is one of the main ways regular users on innocuous pages get funneled toward extremist pages.

Facebooks recommendation algorithm is completely broken down, sending you to ever more extremist content, Newhouse says. Its like a rabbit hole of radicalization. YouTube has been shamed into changing a similar recommendation algorithm, but it remains in place on Facebook. Newhouse goes through a few Related Pages, but nothing alarming comes up.

Next up, Newhouse opens up a website calledIron March Exposed, a database of leaked posts from the now-defunct fascist chat platform Iron March. A keyword search for Monterey yields a post from May 20, 2015 by a user known only as Jakob. Jakob says hes 18 and finishing up high school somewhere in or near Monterey. He says hes an Eagle Scout and a Senior Patrol Leader and his goal is to become a U.S. Air Force pilot. Jakob is also well-read, and he rattles off his fascist credentials: My preferred authors are George Lincoln Rockwell, Julius Evola, Benito Mussolini and Machiavelli, and I have just started reading Mein Kampf, he writes. His classmates just never seemed to get it: I am joining because of the lack of like-minded people around me. I went into high school smoking weed, thinking race-mixing was fine and thinking gays were alright. To end his post, Jakob notes that he is very good at shooting. I grew up around firearms and have plenty of training with rifles and shotguns and handguns alike.

(Deputy Scout Executive Eric Tarbox says he searched the Boy Scouts database but could not identify any Eagle Scout or a Senior Patrol Leader with a matching age and name.)

After Iron March shut down, white supremacists migrated to Discord, among other places. And there was a leak from that platform as well, Newhouse says, while navigating to Discord Leaks, a database hosted by a media outlet called Unicorn Riot. Another place to hunt for hate speech is 4plebs.org, where conversations that took place on 4chan, an anonymous internet forum, are archived.

This type of work is quite manual, and extremism researchers are assisted by their accumulation of knowledge about memes, slang and violent ideologies. Clues such as user names and email addresses can sometimes be tracked and cross-checked on different platforms to discover more details about profiles of users.

But without too many concrete local results, Newhouse moves on another set of techniques those involving the collection of large amounts of data for further analysis. Relatively few social media companies make their data accessible for downloading by researchers and analysts. Examples of transparent companies with what are known as open APIs, or application programming interfaces include Twitter, Reddit and Telegram. (Facebook and Instagram, by contrast, do not allow data to be downloaded in bulk.)

After learning how to download as many as 18,000 tweets at a time, theWeeklywrote some of its own lines of code using the software language R. Every tweet posted over the past week or so and linked to a location within a 30-mile radius of Monterey Countys geographic center entered into a new dataframe. Next, theWeeklysearched the dataframe for certain polarizing terms and codewords, like #Obamagate and QAnon. Many of the resulting tweets were from ordinary people simply remarking on the news of the day. Some led to anonymous accounts like @LawlessBorders located in Freedom, USA and devoted to incendiary anti-immigrant rhetoric. The search also turned up a Santa Cruz resident by the name Justin Rothling. He is a proponent of the QAnon conspiracy theory, according to which a secret cabal of pedophiles within the U.S. government is plotting against President Donald Trump.

Its not always easy to classify online behavior as extremist, and a good example is the case of @DaveOv10, the not-so-well-hidden Twitter identity of Dave Overton, an associate professor of warfare of the Naval War College who teaches at the Naval Postgraduate School in Monterey. At least once, Overton promoted the #plandemic conspiracy theory, which serves to undermine public health efforts aimed at sopping Covid-19. He also a amplifies dangerous rhetoric by using hashtags #EnemyOfThePeople to attack the press. But his primary issue of concern appears to be the exoneration of Michael Flynn, Trumps former national security adviser.

The Michael Flynn cause overlaps with QAnon but is not the same thing, says Marc-Andr Argentino, who is conducting his doctoral research on the QAnon theory at Concordia University. The user probably navigates and consumes similar conservative root media as QAnon adherents, probably also consumes some conspiracy theory content based on his posts, Argentino says.

Overton declined an interview request, but writes by email that the opinions expressed were his and not of any government institution.

Do you want to join the mission to stop hate in Monterey County? A number of local groups make that part of their mission.

This story was edited to clarify that Dave Overton is an employee not of the Naval Postgraduate School but of the Naval War College.

Originally posted here:

Experts taught us how to look for online extremism in Monterey County -- and what we found is surprising. - Monterey County Weekly

Avacta extends partnership with Daewoong Pharmaceutical and AffyXell Therapeutics for Covid-19 stem cell treatments – Cambridge Independent

Avacta has extended its collaboration and license agreement with Daewoong Pharmaceutical Co and their South Korean joint venture AffyXell Therapeutics.

They will develop stem cell treatments incorporating Avactas neutralising Affimer therapy for the treatment of seriously ill patients with Covid-19 and prepare for the rapid development of similar therapies for future global pandemics.

Stem cell therapies offer one potential route to repairing lung tissue damage caused by the immune systems over-reaction to respiratory diseases such as Covid-19.

AffyXell Therapeutics, a next-generation cell and gene therapy joint venture between Whittlesford-based Avacta and Daewoong, is developing mesenchymal stem cell (MSC) treatments engineered to produce Affimer therapies in the patient at the site of action.

The partnership has been extended to include Affimer molecules that target viruses, such as coronaviruses, to develop therapies that repair lung damage, while also producing neutralising Affimer molecules to prevent the progression of the disease.

Under the expanded partnership, AffyXell will engineer mesenchymal stem cells to express SARS-CoV-2 neutralising Affimer molecules to develop treatments for seriously ill Covid-19 patients. It will also prepare for rapid development of next-generation stem cell therapies for future infectious respiratory disease outbreaks.

Avacta CEO Dr Alastair Smith said: I am very pleased to have extended our collaboration and license agreement with Daewoong Pharmaceutical to include the SARS-CoV-2 neutralising Affimer molecules for the treatment of Covid-19 and to create the potential to respond very rapidly in future to global virus threats.

AffyXell will address the need over the coming years for advanced stem cell therapies to treat lung damage caused by cytokine release syndrome suffered by Covid-19 patients and, at the same time, help prevent disease progression in these patients through the action of a neutralising Affimer therapy.

More broadly, one of the key areas of unmet clinical need that AffyXell can address with its next-generation mesenchymal stem cell therapies is acute pulmonary diseases such as COPD and acute respiratory distress syndrome. We, and our partners in South Korea, are very excited by the potential to develop life improving treatments for patients with these serious respiratory diseases as well as Covid-19.

Seng-ho Jeon, CEO of Daewoong Pharmaceutical and AffyXell Therapeutics, said:

It is very encouraging that AffyXell now has the opportunity to expand the application of its next-generation stem cell platform technology to target viruses. The SARS-CoV-2 neutralising Affimer to be developed in combination with AffyXells cell and gene technology is expected to be an innovative solution for COVID-19 patients suffering cytokine release syndrome.

Daewoong has been also conducting several research programs and clinical trial for Covid19. As the Covid-19 crisis has caused great difficulties worldwide, we will continue to focus our efforts to develop a novel therapeutic agent for Covid-19.

Read more

Covid-19 test developed by Avacta and Adeptrix to be evaluated by governments CONDOR programme

Avacta and Integumen collaborate to detect Covid-19 in sewage

Avacta signs distribution deal for Covid-19 self-test under development

Avacta confirms Affimer reagents prevent infection of human cells in model of Covid-19 virus

The rest is here:

Avacta extends partnership with Daewoong Pharmaceutical and AffyXell Therapeutics for Covid-19 stem cell treatments - Cambridge Independent

Three Years After Stem Cell Trial for Heart Failure was Abandoned New Evidence Shows it Works – Diagnostic and Interventional Cardiology

August 4, 2020 - More than three years after a clinical trial was prematurely ended for failing to show progress in healing heart attack scars, the European Heart Journal publishing some surprising results showing that the heart cell treatment does benefit patients.[1]

Data from the ALLSTAR study published Tuesday by the European Heart Journal showed that although infusions of allogeneic cardiac cells (called cardiosphere-derived cells or CDCs) did not appear to shrink the infarct scar after a heart attack, other data from the study show a clear benefit.

Compared with patients who received placebo treatment, patients randomized to receive CDC infusions showed a decrease in the volume of blood in the heart before and after it beats, indicating that the heart had not dilated, as it does progressively in heart failure.

"As it develops heart failure, the heart gets bigger and bigger, like a swelling balloon," said the study's lead author, Raj Makkar, M.D., vice president of cardiovascular innovation and intervention for Cedars-Sinai and the Stephen R. Corday, M.D., chair in interventional cardiology. "One way we can measure the health of a heart is to measure the volume of blood it can hold. The bigger the volume, the more damaged the heart."

The newly analyzed data from the ALLSTAR study, which was sponsored by Capricor Therapeutics, showed that patients given a placebo had hearts that continued to swell, holding larger volumes of blood, while the patients who received CDC infusions had smaller hearts with lower volumes.

The new data results include:

The volume of blood held by the heart was essentially unchanged six months after CDC infusion, but increased by more than a teaspoonful in placebo patients.

A blood protein that measures heart failure severity was reduced in patients who had received CDCs, but not in placebo patients.

The chance that these findings were statistical flukes was only 2 percent.

"To me, these data are very reassuring that there really is therapeutic benefit," said Eduardo Marbn, M.D., Ph.D., executive director of the Smidt Heart Institute. "There is a growing body of evidence that this cell treatment does work."

Results from the earlier CADUCEUS trial, published in The Lancet in 2014, showed that injecting CDCs into the hearts of heart attack survivors significantly reduced infarct size. In 2017, however, the multicenter ALLSTAR study was prematurely halted after six months of data showed no decrease in heart attack scar size, but later analyses revealed the beneficial findings reported here.

"We think we may have chosen the wrong endpoint," said Marbn, the Mark S. Siegel Family Foundation Distinguished Professor, whose discoveries and technologies resulted in CDCs. "This happens in science because you have to design the trial a year or more before you begin, and sometimes you bet on the wrong hors... but that doesnt necessarily mean the therapy is ineffective."

The cells used in the study were CAP-1002, Capricor Therapeutics off-the-shelf, cardiosphere-derived cell (CDC) product candidate. Other clinical trials and case series, in which CDCs were used to treat advanced heart failure, Duchenne Muscular Dystrophy, and COVID-19, also demonstrated positive results. And new studies using CDCs are in the planning stages.

"California is known as the stem cell state, but few technologies being tested in California actually were developed here," said Shlomo Melmed, MB, ChB, executive vice president of Academic Affairs, dean of the Medical Faculty and professor of Medicine. "Increasing evidence-including the results of the large multicenter ALLSTAR trial-validates the potential utility of a cell product which was conceived by a faculty member at Cedars-Sinai, and first tested clinically here."

Read the complete study published by the European Heart Journal.

Disclosures: Except for the cells used in CADUCEUS, the cardiosphere-derived cells used in these studies were derived from donor hearts and provided by Capricor Therapeutics. Marbn developed the process to grow CDCs when he was on the faculty of Johns Hopkins University; the process was further developed at Cedars-Sinai. Capricor has licensed the process from Johns Hopkins and from Cedars-Sinai for clinical and commercial development. Capricor has licensed additional intellectual property from Cedars-Sinai and the University of Rome. Cedars-Sinai and Marbn have financial interests in Capricor.

Reference:

1. Raj R Makkar, Dean J Kereiakes, Frank Aguirre, et al. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. European Heart Journal, ehaa541, https://doi.org/10.1093/eurheartj/ehaa541.

Link:

Three Years After Stem Cell Trial for Heart Failure was Abandoned New Evidence Shows it Works - Diagnostic and Interventional Cardiology

Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook,…

New Jersey, United States,- Market Research Intellect aggregates the latest research on Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market to provide a concise overview of market valuation, industry size, SWOT analysis, revenue approximation, and regional outlook for this business vertical. The report accurately addresses the major opportunities and challenges faced by competitors in this industry and presents the existing competitive landscape and corporate strategies implemented by the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market players.

The Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market report gathers together the key trends influencing the growth of the industry with respect to competitive scenarios and regions in which the business has been successful. In addition, the study analyzes the various limitations of the industry and uncovers opportunities to establish a growth process. In addition, the report also includes a comprehensive research on industry changes caused by the COVID-19 pandemic, helping investors and other stakeholders make informed decisions.

Key highlights from COVID-19 impact analysis:

Unveiling a brief about the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market competitive scope:

The report includes pivotal details about the manufactured products, and in-depth company profile, remuneration, and other production patterns.

The research study encompasses information pertaining to the market share that every company holds, in tandem with the price pattern graph and the gross margins.

Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market, By Type

Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market, By Application

Other important inclusions in the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market report:

A brief overview of the regional landscape:

Reasons To Buy:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Non-Thermal Pasteurization Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Artificial Intelligence in Manufacturing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Hybrid Fiber Coaxial Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Steel Fiber Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

End User Experience Monitoring Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Original post:

Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook,...

IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment…

BRENTWOOD, Tenn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the Company or IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced the United States Food and Drug Administration (the FDA) approved its investigational new drug application, which IMAC submitted in May 2020, for the use of umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss and slowing down of spontaneous body movement, due to Parkinsons disease.

The Company will now initiate enrollment of 15 patients for its Phase 1 trial to evaluate the safety and tolerability of the stem cell product acquired from technology developed by a major research university to treat patients with Bradykinesia due to Parkinsons utilizing intravenous administration of Whartons jelly-derived mesenchymal stem cells. The Company believes that the causes of bradykinesia may be related to an inflammatory response in the body. The Companys new study is designed to confirm this belief and support the Companys long-term strategy for the use of regenerative medicine in combination with physical rehabilitation to reduce the effect of movement-restricting diseases.

Our regenerative rehabilitation centers have long focused on the importance of finding and applying non-opioid, non-surgical solutions to physical ailments in orthopedics. In 2017, our neurosurgeon researched opportunities to apply stem cells to treating Parkinsons, and we put a team together to design a treatment for our neurological patients that simply could not achieve maximum benefit from physical therapy alone, commented Jeffrey Ervin, IMACs Chief Executive Officer. Having received approval to proceed with our study, IMAC is extremely optimistic regarding the potential of this stem cell technology. This has the potential to not only expand proprietary service options for neurological patients, but also advance the way physically debilitating inflammatory conditions are managed as a whole. We would like to thank the FDA for the collaborative process and the partners who helped us achieve this milestone, including patient advocate, Doug Oliver and his team at Regenerative Outcomes.

The Phase 1 trial will consist of three treatment protocols: five patients with bradykinesia due to Parkinsons will receive a low dose intravenous infusion of stem cells, five patients will receive a medium dose intravenous infusion of stem cells and five patients will receive a high dose intravenous infusion of stem cells. The Phase 1 trial will be conducted over 12 months to determine the incidence and extent of adverse events, although the Company will also investigate the efficacy of its stem cell treatment. More information on the clinical trial, including patient criteria, can be found on clinicaltrials.gov.

IMAC will enroll participants from its existing clinics in Illinois, Tennessee, Kentucky and Missouri in its Phase 1 trial. Prospective enrollees may email fdatrial@imacregeneration.com to be considered for the trial. IMACs medical doctors and physical therapists have been trained to administer the treatment and manage the therapy for the clinical trial, which is anticipated to begin in 30 days.

About IMAC Holdings, Inc.

IMAC Holdings was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement restricting diseases and conditions. IMAC owns or manages 16 outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes, opening six Ozzie Smith IMAC Regeneration Centers, two David Price IMAC Regeneration Centers, as well as Mike Ditka IMAC Regeneration Centers and a Tony Delk IMAC Regeneration Center. IMACs outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries and movement-restricting diseases without surgery or opioids. More information about IMAC Holdings, Inc. is available at http://www.imacregeneration.com.

# # #

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as anticipate, expect, believe, may, will, should or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact: Laura Fristoelfristoe@imacrc.com

IMAC Investor Contact:Bret Shapiro(516) 222-2560brets@coreir.com

Source: IMAC Holdings, Inc.

View post:

IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment...

Strathmore man with MS calls for more Canadian treatment alternatives – CTV Toronto

CALGARY -- Hes just 49 years old and already his mobility is mostly confined to his right hand. If Chad Tashlikowich can halt the progression of his primary-progressive Multiple Sclerosis there, hell consider it a victory.

In 2014 Tashlikowich crowd-funded an $80,000 stem cell treatment in Russia hoping to keep him out of an electric wheel chair. That therapy was unsuccessful.

It really hasnt changed the trajectory at all, he says. Despite the risks and expense, his health didnt improve. Its really poor. Its kinda gone down hill really ever since. I dont think the stem cells did a lot,

Now he wants to try a drug treatment ocrevus recommended to him by American Dr Aaron Boster who specializes in MS, a disease that attacks the central nervous system. The problem is, in Canada the drug is not approved for use on patients with Tashlikowichs form of the disease.

You have a mechanic for your car. And if he doesnt do a good job you get another one. You cant do that with a neurologist, Tashlikowich says.

Dr Luanne Metz is a neurology professor at the University of Calgary. Addressing overseas stem cell transplants, she says she understands how MS patients can see some of the treatments as worth the expense and the risk, given their dire prognoses. But she cautions that not all foreign treatment is what its advertised to be, and even when it is, there are medical reasons why guidelines are what they are in Canada.

The problem is, that when people go outside the country for unapproved therapies, they are often not in regulated situations, says Dr. Metz, adding that stem cell therapy does not help primary-progressive MS. She was not speaking about the efficacy of the drug Ocrevus.

Health Canada regulates drug approvals through a rigorous process. Its up to individual provinces to adopt approved treatments from there.

Go here to see the original:

Strathmore man with MS calls for more Canadian treatment alternatives - CTV Toronto

Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma – Dana-Farber Cancer Institute

For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results in clinical trials.

The drugs are the fruit of years of research into improving treatment for multiple myeloma, a cancer of white blood cells known as plasma cells in the bone marrow. Many of the new agents are biologically derived made from substances such as proteins and antibodies found in living things and target biological mechanisms in a very specific, targeted fashion. Dana-Farber researchers have played a key role in these efforts.

These are each powerful examples of how next-generation novel therapies translated here at Dana-Farber from bench to bedside are further improving outcomes for our patients, and at a remarkable pace, says Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber.

Following a Dana-Farber-led clinical trial, the FDA recently approved the novel drug isatuximab in combination with pomalidomide and dexamethasone for adults with relapsed or refractory (non-responsive) myeloma who have received at least two prior therapies, including lenalidomide and drugs known as proteasome inhibitors. The drug went into trials after laboratory work by Dana-Farbers Yu-Tzu Tai, PhD, and Kenneth Anderson, MD, showed it was active against myeloma cells. In the clinical trial, the three-drug combination lowered the risk that the disease would progress by 40%, compared to pomalidome and dexamethasone alone.

Dana-Farber investigators conducted laboratory research and led the first clinical trial of the drug melflufen plus dexamethasone in patients with relapsed or refractory myeloma. Melflufen is a peptide conjugate drug made of a stub of protein, or peptide, joined to a chemotherapy agent and delivers a toxic payload directly to myeloma cells in a selective, time-sparing approach.

Results from an early-phase clinical trial published in Lancet Oncology showed the drug is active in patients with myeloma and is safe at recommended doses. Unlike the previously used standard drug melphalan, it doesnt cause mucositis inflammation of membranes within the digestive tract or hair loss. The results prompted investigators to launch two larger trials, some of whose results are being processed and are due to be published soon.

In a major study published in Blood, Dana-Farber researchers and their associates found that in patients newly diagnosed with myeloma who are eligible for a stem cell transplant, adding the drug daratumumab to the standard three-drug regimen produced more responses, and deeper responses, than in patients receiving the three-drug therapy alone.

Dana-Farber researchers were involved in the development and initial testing of the drug belantamab mafodotin, which has shown considerable promise in clinical trials and has been granted priority review for approval by the FDA.

An antibody conjugate drug consisting of an antibody that specifically targets myeloma cells and an agent that disrupts cell division, its use was informed by a preclinical trial at Dana-Farber involving Yu-Tzu Tai, PhD, and Kenneth Anderson, MD. Balantamab mafodotin was tested in studies led by Paul Richardson, MD, in patients with relapsed or refractory multiple myeloma whose disease continued to worsen after a stem cell transplant, chemotherapy, or other treatment. In the DREAMM-1 and -2 trials, the drug showed strong anti-myeloma activity with manageable side effects.

After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide for the treatment of multiple myeloma. Subsequent studies have focused on next-generation novel drugs including panobinostat and second-generation proteasome inhibitors including ixazomib. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab and more broadly, antibody drug conjugates including belantamab mafodotin, as well as other immunotherapeutic strategies. In addition to these agents, he is leading the development of melflufen, a targeted cytotoxic and an first-in-class small molecule inhibitor selinexor, which inhibits XPO-1, a key nuclear export protein, as well as first-in-human studies of cereblon E3 ligase modulators (so called CELMoDs) for the treatment of relapsed and refractory myeloma.

Over the last decade, his major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with RVD. This regimen has generated an unprecedented response rate, leading to its adoption in this international study, as well as others in the United States and elsewhere. This particular trial incorporates genomic and proteomic evaluation to establish a future platform for tailored therapy and the optimal positioning of stem cell transplant, with results anticipated in 2021-22. Furthermore, RVD has been established as a backbone to which next-generation agents are being added, including elotuzumab, daratumumab and isatuximab, as well as panobinostat.

He has published extensively, having authored or co-authored over 400 original articles and 330 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is prior Chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. He was also a member of ASCO Hematologic Malignancies Subcommittee for the required one-year term, and then for one year on the ASCO Internet Cancer Information Committee during 2017. He was appointed Chair of the Alliance Myeloma Committee in 2011 and continues in this role.

Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, and The Tisch Outstanding Achievement Award for Clinical Research, as well as an honorary Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple Myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway in 2012. He was also a co-recipient of the Accelerator Award for contributions to clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year Award in 2009, followed by the second award for Center of the Year in 2017. He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research in 2016. He was the co-recipient of the ASH Ernest Beutler Prize for clinical science and translational research in the development of proteasome inhibition as an effective treatment strategy for multiple myeloma in 2015; the COMY Award for MM research (Paris, France) in 2016, and the prestigious IMF Robert A. Kyle Lifetime Achievement Award in 2017, and the Morse Research Award in 2019.

Read more:

Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma - Dana-Farber Cancer Institute

ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell Lymphomas – Cancer Network

Nirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.

In a data analysis presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, investigators analyzed whether the use of autologous stem cell transplant in patients with relapsed, chemosensitive DLBCL should remain the standard of care in the CAR T-cell era.

Based on the results of the analysis, it was suggested that autologous transplantation should remain the current standard of care in this patient population.

In an interview with CancerNetwork, Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, spoke about how this analysis could potentially be a benchmark for future studies.

Transcription:

So, we hope to publish our analysis and get it into a peer reviewed journal, so that it becomes available and I think this will be a study that becomes a benchmark that can then be used as a comparator for other clinical trials. I think this gives us a very interesting viewpoint of contemporary data, were PET-CT was used, which is often, you know, a lot of older studies don't utilize PET-CT. So, I think this will be a study that's a benchmark and can be used as a comparison to new therapies that are coming down the road. Because, you know, since, you know, 1980s 1990s, autologous transplant has been that standard of care for relapsed aggressive B-cell lymphoma. And this supports that it should remain that. But it's also possible that over time new therapies do improve upon autologous transplant. But I think this trial will be a nice sort of benchmark to use for future studies.

Excerpt from:

ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell Lymphomas - Cancer Network

Adipose Derived Stem Cell Therapy Market: Technological Advancement & Growth Analysis with Forecast to 2026 – Chelanpress

Market Study Report has added a new report on Adipose Derived Stem Cell Therapy market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising the current and future trends defining the dynamics of this industry vertical, this report also incorporates the regional landscape of Adipose Derived Stem Cell Therapy market in tandem with its competitive terrain.

This Adipose Derived Stem Cell Therapy market report is an integrated document combining a detailed analysis of the industry in question. Combining an in-depth evaluation of this business sphere, the report is also inclusive of an elaborate industry segmentation that contains information about the various segments of the Adipose Derived Stem Cell Therapy market.

Request a sample Report of Adipose Derived Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2695267?utm_source=chelanpress.com&utm_medium=SK

Additionally, the report is inclusive of a detailed outline of this business in tandem with the markets current size and status. Also, the volume and profit parameters have been overviewed in the study. Some pivotal insights pertaining to the regional frame of reference and the competitive spectrum of this industry have been enumerated in the study.

A generic scope of the Adipose Derived Stem Cell Therapy market:

A generic understanding of the competitive landscape

.

Ask for Discount on Adipose Derived Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2695267?utm_source=chelanpress.com&utm_medium=SK

An all-inclusive understanding of the geographical terrain:

A brief summary of the segmentation:

.

.

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-impact-on-global-adipose-derived-stem-cell-therapy-market-size-status-and-forecast-2020-2026

Related Reports:

1. Global Ursodeoxycholic Acid API Market Insights and Forecast to 2026Read More: https://www.marketstudyreport.com/reports/global-ursodeoxycholic-acid-api-market-insights-and-forecast-to-2026

2. Global Wound Cleaning Products Market Insights and Forecast to 2026Read More: https://www.marketstudyreport.com/reports/global-wound-cleaning-products-market-insights-and-forecast-to-2026

Related Report : https://www.marketwatch.com/press-release/underwater-pelletizer-market-analysis-growth-by-top-companies-expected-49-cagr-to-hit-2288-million-by-2026-2020-08-07

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Originally posted here:

Adipose Derived Stem Cell Therapy Market: Technological Advancement & Growth Analysis with Forecast to 2026 - Chelanpress